Skip to main content

Table 4 Calculated doses to the public for each cycle of 177Lu-PSMA-617 therapy for different time points of discharge of the patient from the hospital using different assumptions for the effective half-life

From: External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies

Estimated dose to the public [μSv] after 1 cycle of 177Lu-PSMA-617 therapy

Time point of discharge

24 h p. i.a

48 h p. i.

72 h p. i.b

Type of half-life

T 1/2ind

T 1/2phys

T 1/2max

T 1/2ind

T 1/2phys

T 1/2max

T 1/2ind

T 1/2phys

T 1/2max

Mean

99

396

208

71

263

139

50

200

105

Std. Dev.

58

131

69

51

100

53

35

76

40

Min

25

142

75

13

93

49

17

93

49

Max

318

779

410

264

560

294

204

443

233

  1. aFor the effective individual half-life, the value from the 48-h measurement point was used (see the “Results” section)
  2. bThese data are only available for 25 patients (cohort of Department 2)